Revelation Biosciences Receives Approval To Initiate Phase 2B Viral Challenge Study Of REVTx 99 For Prevention Of Respiratory Viral Infections
T-Reuters
2021-09-28
Petra Acquisition Inc:Revelation Biosciences Inc. Receives Approval To Initiate Phase 2B Viral Challenge Study Of Revtx 99, An Experimental Prophylactic Treatment For Prevention Of Respiratory Viral Infections.Petra Acquisition Inc - Phase 2B Study Will Investigate Efficacy Of Revtx-99 On Viral Load And Patient-Reported Flu Symptoms.Petra Acquisition Inc - Top-Line Data Anticipated In Q2 Of 2022.